THERAPEUTIC EFFECT OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITOR IN THE MALE GENITAL INFLAMMATION

被引：0
|
作者：
Ohira, Shin [1 ]
Hara, Ryoei [1 ]
Tone, Shigenobu [2 ]
Nagai, Atsushi [1 ]
机构：
[1] Kawasaki Med Sch, Dept Urol, Kurashiki, Okayama, Japan
[2] Tokyo Denki Univ, Grad Sch, Dept Life Sci & Engn, Hatoyama, Saitama, Japan
来源：
SEXUALLY TRANSMITTED INFECTIONS | 2019年 / 95卷
关键词：
D O I：
10.1136/sextrans-2019-sti.193
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
O16.1
引用
收藏
页码：A75 / A75
页数：1
相关论文
共 50 条
  • [1] Synthesis of indoleamine 2,3-dioxygenase (IDO) inhibitor
    Suzuki, Takafumi
    Yokoyama, Yuuaku
    Tsutumi, Katsuhiko
    Yamaguchi, Tomoyuki
    Takikawa, Osamu
    Okuno, Hiroaki
    JOURNAL OF MOLECULAR CATALYSIS B-ENZYMATIC, 2010, 62 (01) : 114 - 115
  • [2] Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus
    Romani, Luigina
    Zelante, Teresa
    De Luca, Antonella
    Bozza, Silvia
    Bonifazi, Pierluigi
    Moretti, Silvia
    D'Angelo, Carmen
    Giovannini, Gloria
    Bistoni, Francesco
    Fallarino, Francesca
    Puccetti, Paolo
    MEDICAL MYCOLOGY, 2009, 47 : S154 - S161
  • [3] THERAPEUTIC EFFECT OF INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR IN EPIDIDYMITIS
    Ohira, Shin
    Hara, Ryoei
    Tone, Shigenobu
    Kin, Seitetsu
    Shimizu, Shinjiro
    Fujii, Tomohiro
    Miyaji, Yoshiyuki
    Nagai, Atsushi
    JOURNAL OF UROLOGY, 2017, 197 (04): : E138 - E139
  • [4] THERAPEUTIC EFFECT OF INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR IN THE PROSTATITIS
    Ohira, Shin
    Hara, Ryoei
    Tone, Shigenobu
    Nagai, Atsushi
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1158 - E1158
  • [5] Indoleamine 2,3-dioxygenase (IDO):: the antagonist of type IIFN driven skin inflammation?
    Scheler, M.
    Bieber, T.
    Tueting, T.
    Wenzel, J.
    von Bubnoff, D.
    EXPERIMENTAL DERMATOLOGY, 2007, 16 (03) : 216 - 217
  • [6] The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy
    von Bubnoff, D.
    Bieber, T.
    ALLERGY, 2012, 67 (06) : 718 - 725
  • [7] Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
    Fujiwara, Yu
    Kato, Shumei
    Nesline, Mary K.
    Conroy, Jeffrey M.
    DePietro, Paul
    Pabla, Sarabjot
    Kurzrock, Razelle
    CANCER TREATMENT REVIEWS, 2022, 110
  • [8] Rapid Development of a Commercial Process for Linrodostat, an Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
    Fraunhoffer, Kenneth J.
    DelMonte, Albert J.
    Beutner, Gregory L.
    Bultman, Michael S.
    Camacho, Kathryn
    Cohen, Benjamin
    Dixon, Darryl D.
    Fan, Yu
    Fanfair, Dayne
    Freitag, Adam J.
    Glace, Andrew W.
    Gonzalez-Bobes, Francisco
    Gujjar, Manjunath
    Haley, Matthew W.
    Hickey, Matthew R.
    Ho, Jeanne
    Iyer, Vidya
    Maity, Prantik
    Patel, Sunil
    Rosso, Victor W.
    Schmidt, Michael A.
    Stevens, Jason M.
    Tan, Yichen
    Wilbert, Christopher
    Young, Ian S.
    Yu, Miao
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (11) : 2482 - 2498
  • [9] Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy
    Guo, Yixuan
    Liu, Yu
    Wu, Wei
    Ling, Daishun
    Zhang, Qiao
    Zhao, Peng
    Hu, Xi
    BIOMATERIALS, 2021, 276
  • [10] The therapeutic effect of dendritic cells expressing indoleamine 2,3-dioxygenase (IDO) on an IgA nephropathy mouse model
    Kanghan Liu
    Yiya Yang
    Yinyin Chen
    Shiyao Li
    Yuting Gong
    Yumei Liang
    International Urology and Nephrology, 2020, 52 : 399 - 407
12345